Monoaminergic system and depression

Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review

(2018) P. Molero et al.   CNS DRUGS

Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies

(2018) Francesc Artigas et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

(2018) Nolan R. Williams et al.   AMERICAN JOURNAL OF PSYCHIATRY

Prevalence of Depression in the Community from 30 Countries between 1994 and 2014

(2018) Grace Y. Lim et al.   Scientific Reports

An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms

(2017) Eunsoo Won et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Efficacy of Psychostimulants in Major Depressive Episodes

(2017) Roger S. McIntyre et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

(2016) Zeyad T. Sahli et al.   Expert Opinion on Drug Discovery

Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

(2016) Theo Vos et al.   LANCET

Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data

(2015) Connie Sanchez et al.   PHARMACOLOGY & THERAPEUTICS

Role of Lithium Augmentation in the Management of Major Depressive Disorder

(2014) Michael Bauer et al.   CNS DRUGS

Antidepressant drug development: Focus on triple monoamine reuptake inhibition

(2014) Roger M Lane   JOURNAL OF PSYCHOPHARMACOLOGY

The STAR*D Trial: Revealing the Need for Better Treatments

(2014) Thomas R. Insel et al.   PSYCHIATRIC SERVICES

The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives

(2014) Andre F. Carvalho et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Second-generation antipsychotics in the treatment of major depressive disorder: current evidence

(2013) Changsu Han et al.   Expert Review of Neurotherapeutics

Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs

(2013) L Perez-Caballero et al.   MOLECULAR PSYCHIATRY

Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010

(2013) Alize J. Ferrari et al.   PLOS MEDICINE

Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature

(2012) A. J. Ferrari et al.   PSYCHOLOGICAL MEDICINE

The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder

(2011) Ricardo Moreira   CLINICAL DRUG INVESTIGATION

Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression

(2010) Michael E. Thase et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

(2010) Christian de Bodinat et al.   NATURE REVIEWS DRUG DISCOVERY

Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials

(2009) J. Craig Nelson et al.   AMERICAN JOURNAL OF PSYCHIATRY

Opiates as Antidepressants

(2009) Esther Berrocoso et al.   CURRENT PHARMACEUTICAL DESIGN

Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today

(2009) Francisco Lopez-Munoz et al.   CURRENT PHARMACEUTICAL DESIGN

The molecular neurobiology of depression

(2008) Vaishnav Krishnan et al.   NATURE